The Impact of Clinical Variables and Dialysis Modality on Kynurenine Pathway Enzymes Expression
Open Access
- 28 January 2026
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (3) , 1313
Abstract
Chronic kidney disease (CKD) and kidney failure significantly reduce patients’ quality of life and markedly increase cardiovascular risk and overall mortality. Disturbed metabolism of tryptophan (Trp) through kynurenine (KYN) pathway was implicated as an important factor in kidney damage and its complications. However, the expression of genes coding crucial enzymes of KYN pathway was not examined so far. The goal of the present study was to analyze the expression of Ido (indoleamine-2,3-dioxygenase), Kat1 (kynurenine aminotransferase 1), Kat2 (kynurenine aminotransferase 2), and Kmo (kynurenine-3-monooxygenase) genes in patients undergoing kidney failure with kidney replacement therapy (KFRT) treatment with either hemodiafiltration (HDF) or hemodialysis (HD) in relation to selected clinical and dialysis parameters. Our data imply that Ido, Kat1, and Kmo gene expression does not differ between KFRT patients with analyzed comorbidities, vascular access types, or diuresis occurrence. However, Ido and Kmo gene expression correlated with pre-dialysis concentration or reduction ratio (RR) of selected metabolites. Interestingly, patients treated with HDF manifested lower Kmo gene expression in comparison with patients treated by HD. Our study suggests that epigenetic factors do not exert noticeable impact on the KYN pathway enzymes expression in patients with KFRT. The advantageous effect of HDF vs. HD towards the KYN pathway genes expression has potential therapeutic implications, as it may reflect superiority of the former method in KFRT patients.Keywords
Funding Information
- Medical University of Lublin, Poland (384/2024)
- Medical University of Lublin, Poland (384/2025)
- Medical University of Lublin, Poland (450/2024)
- Medical University of Lublin, Poland (450/2025)
This publication has 40 references indexed in Scilit:
- Uncovering the Link Between Kynurenic Acid Pathway and Kidney FailureKidney International Reports, 2025
- Serum tryptophan and kynurenine levels and risk of heart failure among patients with chronic kidney diseaseClinical Nutrition, 2025
- Tryptophan catabolism via the kynurenine pathway regulates infection and inflammation: from mechanisms to biomarkers and therapiesInflammation Research, 2024
- Residual Kidney Function and Cause-Specific Mortality Among Incident Hemodialysis PatientsKidney International Reports, 2023
- Kynurenine pathway in kidney diseasesPharmacological Reports, 2021
- Abnormal kynurenine pathway of tryptophan catabolism in cardiovascular diseasesCellular and Molecular Life Sciences, 2017
- Optimization of Zn2+-containing mobile phase for simultaneous determination of kynurenine, kynurenic acid and tryptophan in human plasma by high performance liquid chromatographyJournal of Chromatography B, 2010
- Kynurenines and oxidative status are independently associated with thrombomodulin and von Willebrand factor levels in patients with end-stage renal diseaseThrombosis Research, 2009
- Induction of indolamine 2,3-dioxygenase and kynurenine 3-monooxygenase in rat brain following a systemic inflammatory challenge: A role for IFN-γ?Neuroscience Letters, 2008
- NO CHANGE IN CORRECTED β2-MICROGLOBULIN CONCENTRATION AFTER CUPROPHANE HAEMODIALYSISThe Lancet, 1987